TAN-118
/ Shanghai Thederma Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 06, 2025
To evaluate the safety and tolerability of TAN-118 tablets in healthy adult subjects
(ChiCTR)
- P1 | N=92 | Not yet recruiting | Sponsor: Nanjing First Hospital; Shanghai Thederma Pharmaceutical Technology Co., Ltd
New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1